These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8731957)

  • 21. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
    Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
    Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of neferine and its combination with taurine on platelet aggregation and experimental thrombosis in rats].
    Huang HL; Rao MR
    Yao Xue Xue Bao; 1995; 30(7):486-90. PubMed ID: 7484155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.
    Tepe G; Schott U; Erley CM; Albes J; Claussen CD; Duda SH
    AJR Am J Roentgenol; 1999 May; 172(5):1343-6. PubMed ID: 10227513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
    Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
    Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir).
    Schneider J; Wnendt S; Saunders D; Heinzel-Wieland R; Wilffert B; Steffens G
    Eur J Pharmacol; 1996 Apr; 302(1-3):69-77. PubMed ID: 8790994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of rhyncophylline on platelet aggregation and experimental thrombosis].
    Jin RM; Chen CX; Li YK; Xu PK
    Yao Xue Xue Bao; 1991; 26(4):246-9. PubMed ID: 1957668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The observation of changes in plasma PGI2 and TXA2 levels and the therapeutic effect of tetramethylpyrazine in E. coli induced acute lung injury in rabbits].
    Li B
    Zhonghua Jie He He Hu Xi Za Zhi; 1991 Jun; 14(3):143-5, 189. PubMed ID: 1913959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of dahuangzhechong pills on anti-arterial thrombosis with the orthogonal design].
    Wei X; Wang ZY; Li JY; Wan L; He FY; Duan XP; Zhong GW; Jiang Y; Wang DS
    Zhong Yao Cai; 2012 Jan; 35(1):106-11. PubMed ID: 22734422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
    Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
    Curl GR; Jakubowski JA; Nabseth DC; Bush HL
    Arch Surg; 1986 Jul; 121(7):782-8. PubMed ID: 3087327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolytic and Antiplatelet Effects of a Novel Plasminogen Activator from the Venom of Gloydius Brevicaudus Viper.
    Zhang Z; Lin L; Zhang J; Zhang Q; Zhao N; Wu L; Chen J; Wu Z; Wu G; Lin J; Chen Y; Xu Y
    J Atheroscler Thromb; 2015; 22(10):1080-90. PubMed ID: 26004931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibitory effects of new-breviscapine on thrombosis in vivo].
    Wang ZY
    Zhong Xi Yi Jie He Za Zhi; 1989 Jan; 9(1):26-8, 6. PubMed ID: 2776271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
    Terres W; Umnus S; Mathey DG; Bleifeld W
    Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet aggregation and thromboxane B2 release in patients with acute myocardial infarction--their relation to coronary patency.
    Takatsu Y; Yui Y; Hattori R; Sakaguchi K; Susawa T; Yui N; Takahashi M; Aoyama T; Tamaki S; Kawai C
    Jpn Circ J; 1988 Apr; 52(4):314-20. PubMed ID: 3385913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ; Connolly TM; York SJ; Bush LR
    Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombolytic therapy: enhancement by platelet and platelet-derived mediator antagonists.
    Willerson JT; Golino P; McNatt J; Eidt J; Yao SK; Buja LM
    Mol Biol Med; 1991 Apr; 8(2):235-43. PubMed ID: 1806765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.